BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 12, 2006
 |  BioCentury  |  Strategy

Back in the limelight

Désiré Collen, one of the developers of Activase alteplase tissue-plasminogen activator, has been working on next-generation products since the time t-PA went on the market in 1987. For the most part, the work has been financed with royalties from t-PA. But with products moving through the clinic, his company, ThromboGenics N.V., has announced plans to go public on Euronext in Belgium.

Collen, whose laboratory was the first to produce t-PA for clinical use, thinks the company's staphylokinase could have efficacy similar to t-PA at a lower cost of goods. The plasminogen activator is in Phase II trials. ThromboGenics' second product, microplasmin, is a direct-acting thrombolytic in Phase II studies.

"The first experiments suggesting that staphylokinase had potential were done in 1989," said Collen, who is chairman and CEO. In 1991, Collen and colleagues at the Katholieke Universiteit Leuven spun out Thromb-X N.V. to develop staphylokinase. The company received E600,000 ($775,380) in seed money.

Starting in 1993, Thromb-X acquired a growing percentage of the t-PA royalty stream the university was receiving from Genentech Inc....

Read the full 886 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >